Market reactionShares rose 13% on Nov 5.
Ironwood shares U.S. LINZESS profits with AbbVie for constipation disorders and is developing apraglutide, a weekly injection for short bowel syndrome that is not yet approved.
Ironwood earns half the U.S. LINZESS profits shared with AbbVie. Net price recovered in 2026: LINZESS U.S. sales were $282 million in the second quarter, and guidance rose to $1.15-1.20 billion. The business generates cash; Ironwood repaid $200 million of notes but owes $385 million on its revolver. Growth beyond LINZESS rests on apraglutide, a weekly GLP-2 drug. Its first Phase 3, STARS, was positive, but FDA required a confirmatory trial, STARS-2, which is now enrolling.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: STARS-2 confirms apraglutide
Does STARS-2 confirm that weekly apraglutide reduces parenteral support versus placebo?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
LINZESS sales rebounded in 2026; apraglutide's confirmatory Phase 3 is enrolling
A LINZESS-funded pivot into SBS-IF with apraglutide, where STARS-2 Phase 3 results against teduglutide's established position will decide the thesis
FDA approves LINZESS for pediatric IBS-C (ages 7+)
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
1 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.